The role of tumor necrosis factor-alpha and other cytokines in depression: what dermatologists should know

References

• Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol. 2010;62:812–818.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol. 2008;159:704–710.
   PubMed Web of Science ®Google Scholar
• Evers AW, Lu Y, Duller P, van der Valk PG, Kraaimaat FW, van de Kerkhof PC. Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis. Br J Dermatol. 2005;152:1275–1281.
   PubMed Web of Science ®Google Scholar
• Tobin AM, Kirby B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs. 2005;19:47–57.
   PubMed Web of Science ®Google Scholar
• Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S, Depression, comorbidities and the TNF-alpha system. Eur Psychiatry. 2008;23:421–429.
   PubMed Web of Science ®Google Scholar
• Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46–56.
   PubMed Web of Science ®Google Scholar
• Soczynska JK, Kennedy SH, Goldstein BI, Lachowski A, Woldeyohannes HO, McIntyre RS. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression? Neurotoxicology. 2009;30:497–521.
   PubMed Web of Science ®Google Scholar
• Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24–31.
   PubMed Web of Science ®Google Scholar
• Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446–457.
   PubMed Web of Science ®Google Scholar
• Clark IA, Alleva LM, Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacol Ther. 2010;128:519–548.
   PubMed Web of Science ®Google Scholar
• Janelidze S, Mattei D, Westrin A, Traskman-Bendz L, Brundin L. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav Immun. 2011;25:335–339.
   PubMed Web of Science ®Google Scholar
• Wichers M, Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol. 2002;5:375–388.
   PubMed Web of Science ®Google Scholar
• Kent S, Bluthe RM, Kelley KW, Dantzer R. Sickness behavior as a new target for drug development. Trends Pharmacol Sci. 1992;13:24–28.
   PubMed Web of Science ®Google Scholar
• Krueger JM, Takahashi S, Kapas L, Bredow S, Roky R, Fang J, Cytokines in sleep regulation. Adv Neuroimmunol. 1995;5:171–188.
   Google Scholar
• Brebner K, Hayley S, Zacharko R, Merali Z, Anisman H. Synergistic effects of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha: central monoamine, corticosterone, and behavioral variations. Neuropsychopharmacology. 2000;22:566–580.
   PubMed Web of Science ®Google Scholar
• Bianchi M, Sacerdote P, Ricciardi-Castagnoli P, Mantegazza P, Panerai AE. Central effects of tumor necrosis factor alpha and interleukin-1 alpha on nociceptive thresholds and spontaneous locomotor activity. Neurosci Lett. 1992;148:76–80.
   Google Scholar
• Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord. 2002;72:237–241.
   PubMed Web of Science ®Google Scholar
• Krueger C, Hawkins K, Wong S, Enns MW, Minuk G, Rempel JD. Persistent pro-inflammatory cytokines following the initiation of pegylated IFN therapy in hepatitis C infection is associated with treatment-induced depression. J Viral Hepat. 2011;18:e284–91.
   Google Scholar
• Clement HW, Buschmann J, Rex S, Grote C, Opper C, Gemsa D, Effects of interferon-gamma, interleukin-1 beta, and tumor necrosis factor-alpha on the serotonin metabolism in the nucleus raphe dorsalis of the rat. J Neural Transm. 1997;104:981–991.
   PubMed Web of Science ®Google Scholar
• Himmerich H, Binder EB, Kunzel HE, Schuld A, Lucae S, Uhr M, Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. Biol Psychiatry. 2006;60:882–888.
   PubMed Web of Science ®Google Scholar
• Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MB. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int Immunopharmacol. 2006;6:903–907.
   PubMed Web of Science ®Google Scholar
• Hannestad J, DellaGioia N, Ortiz N, Pittman B, Bhagwagar Z. Citalopram reduces endotoxin-induced fatigue. Brain Behav Immun. 2011;25:256–259.
   PubMed Web of Science ®Google Scholar
• Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367:29–35.
   PubMed Web of Science ®Google Scholar
• Modell JG, Boyce S, Taylor E, Katholi C. Treatment of atopic dermatitis and psoriasis vulgaris with bupropion-SR: a pilot study. Psychosom Med. 2002;64:835–840.
   PubMedGoogle Scholar